8-K: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Relmada Therapeutics announced a corporate update and preliminary financial results for the fourth quarter and full year 2023, highlighting progress in their Phase 3 clinical trials for REL-1017 and the initiation of a Phase 1 trial for their psilocybin program.

Summary

• Relmada Therapeutics is advancing its Phase 3 program for REL-1017 as an adjunctive treatment for major depressive disorder (MDD).
• Enrollment in the Reliance II study is progressing, with top-line data expected in the second half of 2024.
• The Relight study began dosing patients in the third quarter of 2023 and is expected to complete enrollment by the end of 2024.
• A Phase 1 trial for the low-dose metabolic psilocybin program (REL-P11) is planned for the first half of 2024 in obese patients, followed by a Phase 2a trial.
• Research and development expenses decreased to $14.8 million for the fourth quarter of 2023, compared to $26.9 million in the same period of 2022.
• General and administrative expenses increased slightly to $12.1 million for the fourth quarter of 2023, compared to $11.8 million in the same period of 2022.
• Net cash used in operating activities for the fourth quarter of 2023 was $10.3 million, compared to $35.9 million in the same period of 2022.
• The net loss for the fourth quarter of 2023 was $25.2 million, or $0.84 per share, compared to a net loss of $37.9 million, or $1.28 per share, for the same period in 2022.
• For the full year 2023, research and development expenses totaled $54.8 million, compared to $113.3 million in 2022.
• General and administrative expenses for the full year 2023 were $48.9 million, compared to $47.9 million in 2022.
• Net cash used in operating activities for the full year 2023 was $51.7 million, compared to $103.8 million in 2022.
• The net loss for the full year 2023 was $98.8 million, or $3.28 per share, compared to a net loss of $157.0 million, or $5.30 per share, in 2022.
• As of December 31, 2023, the company had approximately $96.3 million in cash, cash equivalents, and short-term investments, compared to $148.3 million at the end of 2022.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and improved financial metrics, but the company is still operating at a loss and has decreasing cash reserves.

Positives

• The company is progressing with its late-stage clinical trials for REL-1017.
• The initiation of a Phase 1 trial for the psilocybin program is a positive step for the company's pipeline.
• The decrease in research and development expenses indicates improved cost management.
• The reduction in net losses and cash used in operations suggests improved financial performance.
• The company maintains a reasonable cash position of $96.3 million.

Negatives

• The company experienced a net loss of $98.8 million for the full year 2023.
• Cash reserves have decreased from $148.3 million to $96.3 million year-over-year.
• General and administrative expenses have increased slightly year-over-year.

Risks

• Clinical trial results may not demonstrate statistically significant efficacy or safety.
• Top-line results may not accurately reflect the complete trial results.
• The company may fail to obtain regulatory approval for REL-1017.
• The planned psilocybin trials may not be successfully initiated or carried out.
• The company's cash reserves are decreasing.

Future Outlook

The company anticipates top-line data from the Reliance II study in the second half of 2024, completion of enrollment in the Relight study by the end of 2024, and initiation of a Phase 1 trial for the psilocybin program in the first half of 2024, followed by a Phase 2a trial with data expected in the first half of 2025.

Management Comments

• Sergio Traversa, Relmada's Chief Executive Officer, stated that they continue to make solid progress in advancing their Phase 3 program for REL-1017.
• Mr. Traversa also mentioned the initiation of a Phase 1 trial for their psilocybin program.

Industry Context

This announcement is relevant to the biotechnology and pharmaceutical industries, particularly companies focused on central nervous system (CNS) disorders and mental health treatments. The progress in clinical trials and the exploration of psilocybin for therapeutic use are aligned with current trends in the industry.

Comparison to Industry Standards

• Relmada's decrease in R&D spending is notable, as many biotech companies often see increases in this area as they progress through clinical trials. This could indicate a more efficient use of resources or a shift in focus.
• The company's cash burn rate has decreased significantly year-over-year, which is a positive sign for investors. However, the remaining cash balance of $96.3 million is relatively low for a company in late-stage clinical development, and may require further capital raising.
• The company's focus on novel treatments for MDD and the exploration of psilocybin aligns with the industry's growing interest in alternative therapies for mental health conditions. Companies like Compass Pathways and MindMed are also exploring psilocybin-based treatments, making this a competitive space.
• The company's net loss per share of $3.28 for 2023 is a significant improvement compared to $5.30 in 2022, but still indicates a need for the company to achieve profitability.

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and improved financial performance.
• Employees may be impacted by changes in compensation and the company's overall financial health.
• Patients may benefit from the development of new treatments for major depressive disorder and other CNS conditions.
• Creditors may be concerned about the company's decreasing cash reserves.

Next Steps

• Complete enrollment in the Reliance II study and report top-line data in the second half of 2024.
• Complete enrollment in the Relight study by the end of 2024.
• Initiate a Phase 1 trial for the psilocybin program in the first half of 2024, followed by a Phase 2a trial.
• File the complete audited financial statements in the Annual Report on Form 10-K.

Key Dates

Keywords

REL-1017, psilocybin, clinical trials, major depressive disorder, MDD, CNS, biotechnology, pharmaceuticals, research and development, financial results